- Home
- ANTX
as of 12-23-2025 10:50am EST
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 30.1M | IPO Year: | 2022 |
| Target Price: | $2.00 | AVG Volume (30 days): | 61.1K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.01 - $1.55 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of AN2 Therapeutics Inc. (ANTX)
See Remarks
Avg Cost/Share
$1.14
Shares
2,819
Total Value
$3,213.66
Owned After
177,353
SEC Form 4
Chief Strategy Officer
Avg Cost/Share
$1.14
Shares
765
Total Value
$872.10
Owned After
65,548
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Eizen Joshua M | ANTX | See Remarks | Nov 4, 2025 | Sell | $1.14 | 2,819 | $3,213.66 | 177,353 | |
| Prior Stephen David | ANTX | Chief Strategy Officer | Nov 4, 2025 | Sell | $1.14 | 765 | $872.10 | 65,548 |
Compare ANTX vs Leading Stocks
See how ANTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ANTX AN2 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.